血蛋白质学确定了糖尿病多神经病的潜在药物标:来自潜在队列和遗传分析的证据
Haoning Lan1, Songchao Xu1, Huili Li1
1Department of Anaesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Diabetes, obesity & metabolism
|October 27, 2025
概括
研究人员将TNFRSF14确定为糖尿病多神经病 (DP) 中的关键蛋白质. 这一发现为早期检测和有效治疗PD提供了潜在的新目标,改善了患者的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
背景情况:
- 糖尿病多神经病 (DP) 缺乏有效的向疗法.
- 确定新的治疗点对于提高PD治疗疗效至关重要.
研究的目的:
- 为了确定糖尿病多神经病 (DP) 的新型蛋白质标.
- 调查已识别的蛋白质在DP病原和临床表现中的作用.
主要方法:
- 大规模临床和遗传数据集的分析.
- 蛋白质与DP症状和风险因素的相关性研究.
- 单细胞测序以探索致病机制.
主要成果:
- 确定了六种与DP相关的蛋白质.
- TNFRSF14与PD严重程度有很强的相关性 (密歇根州神经病学查仪).
- TNFRSF14可能会调解代谢综合征对DP的影响,并涉及巨细胞激活和内皮细胞功能障碍.
结论:
- TNFRSF14是早期DP检测的一个有前途的生物标志物.
- TNFRSF14代表了特定DP治疗的潜在治疗标.
- 准TNFRSF14可能会导致糖尿病多神经病变患者的治疗结果改善.
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
17
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
17
Diabetic Retinopathy
55
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
55
Diabetic Nephropathy
32
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
32
Diabetic Neuropathy
59
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
59


